

Supporting Information

Catalyst-free One-Pot, Four-Component Approach for the Synthesis of di- and tri-substituted N-Sulfonyl formamidines

Ai-Ran Liu,^a Lei Zhang,^a Jiao Li,^a Abudurehman Wusiman^{a, b*}

^a School of Chemistry and Chemical Engineering, Xinjiang Normal University,

Urumqi 830054, China; E-mail: arahman@xjnu.edu.cn

^b Xinjiang Key Laboratory of Energy Storage and Photoelectrocatalytic Materials,
Urumqi 830054, China

Content

1. General Information.....	S1
2. Experimental section.....	S2
3. Crystal Structure of Products 5c and 5r	S4
4. The Mechanistic Investigation.....	S6
4. Characterization of the Products.....	S7
5. References	S19
6. Copies of ¹ H and ¹³ C NMR Spectra.....	S20

1. General Information:

All the solvents and commercial reagents were used without additional purification. Purification of the reaction products was carried out by flash column chromatography using 200-300 mesh silica gel. Visualization on TLC (analytical thin layer chromatography) was achieved by the use of UV light (254 nm). High-resolution mass spectra were recorded on a Bruker BIO TOF Q mass spectrometer. Proton and carbon magnetic resonance spectra (^1H NMR and ^{13}C NMR) were recorded on a Varian Inova 400 MHz (^1H NMR at 400 MHz and ^{13}C NMR at 100 MHz) spectrometer with solvent resonance as the internal standard (^1H NMR: CDCl_3 at 7.26 ppm, $\text{DMSO-}d_6$ at 2.50 ppm; ^{13}C NMR: CDCl_3 at 77.02 ppm, $\text{DMSO-}d_6$ at 39.52 ppm). ^1H NMR data are reported as follows: chemical shifts, multiplicity (s = singlet, br s = broad singlet, d = doublet, dd = doublet of doublet, t = triplet, q = quartet, m = multiplet), coupling constant(s) in Hz, integration. Single-crystal X-ray diffraction was carried out on a Agilent SuperNova, Dual, Cu at zero, AtlasS2 diffractometer with graphite monochromated Cu $K\alpha$ radiation ($\lambda = 0.71073 \text{ \AA}$) at 100.00(10) K.

2. Experimental Section

2.1 Di-substituted *N*-sulfonyl formamidine

General procedure for the synthesis of di substituted sulfonyl formamidines 5a-5m;

In a 5 mL screw cap vial with a stir bar, ethyl propiolate (0.5 mmol, 49.1mg) and primary amine (0.5 mmol) were dissolved in acetonitrile (1.0 mL) and stirred at room temperature for 1h, and then the NaN_3 (0.75 mmol, 48.8 mg) and sulfonyl chloride (0.75 mmol) solution (in 1.0 mL acetonitrile) were added gradually to reaction mixture and stirred at room temperature until the enaminoester intermediate was fully consumed (reaction was monitored with TLC). The reaction mixture was poured into 10 ml of water and extracted with 20 mL of dichloromethane (3 times) and the combined organic layer was dried over sodium sulfate. Organic solvents were removed under reduced pressure and the crude reaction mixture was purified by column chromatography on silica gel column (ethyl acetate /petroleum ether) to afford the desired products.

A gram-scale synthesis of *N*-butyl-*N'*-(phenylsulfonyl)formimidamide (5b)

A solution of ethyl propiolate (10 mmol, 0.98 g) and *n*-butyl amine (10 mmol, 0.73g) in acetonitrile (10 mL) was stirred at room temperature for 1h, and then the NaN_3 (15 mmol, 0.98 g) and benzene sulfonyl chloride (15 mmol, 1.77 g) solution (in 10 mL acetonitrile) were added gradually to reaction mixture and stirred at room temperature until the enaminoester intermediate was fully consumed (7 h). The reaction mixture was poured into 30 ml of water and extracted with 70 mL of dichloromethane (3 times) and the combined organic layer was dried over sodium sulfate. Organic solvents were removed under reduced pressure and the crude reaction mixture was purified by column chromatography on silica gel column (ethyl acetate /petroleum ether) to afford the desired products **5b** (74% yield, 1.78 g).

2.3 Tri-substituted sulfonyl formamidine

Table 1. Optimization of reaction conditions for tri- substituted *N*-sulfonyl formamidine ^a

Entry	Solvent(s)/(v : v)	Temp.	t (h)	Yield (%) ^b
1	MeCN	rt	12	38
2	H ₂ O	rt	12	46
3	H ₂ O/THF=3:1	rt	12	43
4	H ₂ O/Acetone=3:1	rt	12	55
5	H ₂ O/DMF=3:1	rt	12	50
6	H ₂ O/DMA=3:1	rt	12	48
7	H ₂ O/MeOH=3:1	rt	12	52
8	H ₂ O/EtOH=3:1	rt	12	57
9	H ₂ O/EtOH=1:1	rt	12	66
10	H ₂ O/EtOH=1:2	rt	12	70
11	EtOH	rt	12	74
12 ^c	EtOH	rt	12	67
13	EtOH	30 °C	8	83
14	EtOH	40 °C	6	91
15	EtOH	50 °C	5	90
16 ^d	EtOH	40 °C	5	65

^a Reactions were performed with **1a** (1.5 mmol), **2** (1.5 mmol), **3** (1 mmol), **5a** (1 mmol) in 4 mL solvent in a 10 mL round-bottom flask at room temperature under open-air condition, unless otherwise noted. ^b Isolated yield after column chromatography. ^c **1a** and **2** were 1.2 mmol. ^d 3-Butyn-2-one was used instead of ethyl propiolate (**3**).

General procedure for the synthesis of tri-substituted *N*-sulfonyl formamidines **7a-7n**;

In a 10 mL of round bottom flask with a stir bar, ethyl propiolate (1 mmol, 98.1mg) and secondary amine (1 mmol) were stirred at room temperature for 5 min, and then ethanol (4 mL), NaN₃ (1.5 mmol, 65.1 mg) and sulfonyl chloride (1.5 mmol) were added gradually and reaction temperature was increased to 40 °C and stirred until the enaminoester intermediate was fully consumed (reaction was monitored with TLC). After cooling to room temperature, the solvent was removed under reduced pressure and the crude reaction mixture was purified by column chromatography on silica gel column (ethyl acetate /petroleum ether) to afford the desired products.

3. Crystal Structure of Products 5c and 5r

The single crystals of **5c** (*E-syn*) and **5r** (*E-anti*) were obtained with suitable quality from their *E-syn/anti* mixture respectively (DCM was solvent), and analyzed by single crystal diffractometer (SuperNova, Dual, Cu at zero, AtlasS2). Atomic coordinates, bond lengths, bond angles, and thermal parameters have been deposited at the Cambridge Crystallographic Data Centre. CCDC deposit number are 2055587 (**5c**) and 2055586 (**5r**) respectively.




Figure S1: Crystal XRD image of **5c** (*E-syn*)




Figure S2: Crystal XRD image of **5r** (*E-anti*)

Table 1 Crystal data and structure refinement for compounds 5c and 5r.

Compound	5c	5r
Empirical formula	C ₁₁ H ₁₅ N ₃ O ₄ S	C ₁₁ H ₁₅ N ₃ O ₄ S
Formula weight	285.32	285.32
Temperature/K	150.00(10)	100.01(10)
Crystal system	monoclinic	orthorhombic
Space group	P2 ₁ /c	Pccn
a/Å	6.2139(3)	9.2057(7)
b/Å	18.1514(10)	24.8117(16)
c/Å	12.4052(7)	12.0592(8)
α /°	90	90
β /°	97.612(5)	90
γ /°	90	90
Volume/Å ³	1386.86(13)	2754.4(3)
Z	4	8
ρ_{calc} /cm ³	1.366	1.376
μ /mm ⁻¹	0.247	0.249
F(000)	600.0	1200.0
Crystal size/mm ³	0.14 × 0.13 × 0.12	0.14 × 0.12 × 0.11
Radiation	Mo K α (λ = 0.71073)	Mo K α (λ = 0.71073)
2 Θ range for data collection/°	4 to 49.994	4.72 to 49.992
Index ranges	-5 ≤ h ≤ 7, -21 ≤ k ≤ 17, -14 ≤ l ≤ 12	-7 ≤ h ≤ 10, -29 ≤ k ≤ 23, -10 ≤ l ≤ 14
Reflections collected	5763	7104
Independent reflections	2451 [R _{int} = 0.0246, R _{sigma} = 0.0346]	2427 [R _{int} = 0.0271, R _{sigma} = 0.0292]
Data/restraints/parameters	2451/7/173	2427/0/175
Goodness-of-fit on F ²	1.078	1.076
Final R indexes [I ≥ 2 σ (I)]	R ₁ = 0.0413, wR ₂ = 0.1061	R ₁ = 0.0414, wR ₂ = 0.0994
Final R indexes [all data]	R ₁ = 0.0483, wR ₂ = 0.1132	R ₁ = 0.0482, wR ₂ = 0.1044
Largest diff. peak/hole / e Å ⁻³	0.59/-0.38	0.25/-0.41

4. The Mechanistic Investigation

4.1. NMR monitoring study for the crude reaction mixture

In a 5mL screw cap vial with a stir bar tosyl azide (0.75 mmol) and ethyl 3-(butylamino) acrylate were dissolved in acetonitrile (2.0 mL) and stirred at room temperature for 4h, solvent was removed and then recorded the ^1H NMR spectra of cured reaction mixture.

From a crude ^1H NMR spectrum of the reaction mixture (Figure S3. section 2) we observed the desired product **5a** and *N*-butyltosyl amide as well as 4-ethoxycarbonyl-1H-1,2,3-triazole, this result attributed that this reaction could generate other by-products beside the ethyldiazoacetate .






Figure S3: ^1H NMR of crude reaction mixture


5. Characterization of the Products



***N*-butyl-*N'*-(tosyl)formimidamide (E-*syn/anti*=7:3) (5a):** yellow oil, 41.4 mg, 67% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.28 (d, $J=5.2$ Hz, 0.70H), 8.07 (d, $J=13.6$ Hz, 0.3H), 7.71 (t, $J=8.8$ Hz, 2H), 7.25 (t, $J=8.8$ Hz, 2H), 7.05(bs, 0.3H), 6.42 (bs, 0.7H), 3.33 (q, $J=6.8$ Hz, 1.4H), 3.6 (q, $J=6.8$ Hz, 0.6H), 2.38 (s, 3H), 1.70, 1.52-1.46 (m, 2H), 1.33-1.23 (m, 2H), 0.91-0.83 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.30, 157.90, 142.87, 142.53, 139.28, 138.90, 129.49, 129.33, 126.37, 126.34, 46.19, 41.55, 32.43, 30.43, 21.46, 19.84, 19.48, 13.58, 13.49. HRMS (ESI): calculated for $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 255.1162; found: 255.1166.




***N*-butyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=7:3) (5b):** yellow oil, 96.1 mg, 80% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.32(d, $J=5.2$ Hz, 0.7H), 8.13 (d, $J=13.2$ Hz, 0.3H), 7.85 (t, $J=6.8$ Hz, 2H), 7.55-7.44 (m, 3H), 7.28, 6.77 (bs, 0.7H), 3.39-3.31 (m, 2H), 1.56-1.48 (m, 2H), 1.60-1.50 (m, 2H), 1.35-1.26 (m, 2H), 0.93-0.85 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.37, 158.11, 142.26, 141.77, 132.26, 131.93, 128.95, 128.75, 126.36, 46.34, 41.62, 32.38, 30.45, 19.85, 19.50, 13.56, 13.47. HRMS (ESI): calculated for $\text{C}_{11}\text{H}_{17}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 241.1005; found: 241.1006.




***N*-butyl-*N'*-((4-nitrophenyl)sulfonyl)formimidamide (E-*syn/anti*=7:3) (5c):** white solid, 114.1 mg, 80% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.31-8.29 (m, 2.7H), 8.12 (d, $J=13.6$ Hz, 0.3H), 8.06-8.01(m, 2H), 7.25, 6.76 (bs, 0.3H), 6.30 (bs, 0.7H),


3.42-3.34 (m, 2H), 1.60-1.50 (m, 2H), 1.35-1.27 (m, 2H), 0.94-0.86 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.70, 158.16, 149.72, 149.64, 147.80, 147.51, 127.78, 124.14, 124.05, 46.39, 41.85, 32.32, 30.42, 19.81, 19.47, 13.53, 13.45. HRMS (ESI): calculated for $\text{C}_{11}\text{H}_{16}\text{N}_3\text{O}_4\text{S}$ $[\text{M}+\text{H}]^+$: 286.0856; found: 286.0869.




***N*-butyl-*N'*-((2-chlorophenyl)sulfonyl)formimidamide (*E*-*syn/anti*=7:3) (5d):** yellow oil, 127.6 mg, 93% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.43 (d, J = 5.2Hz, 0.7H), 8.19 (d, J = 15 Hz, 0.3H), 8.16 (d, J = 8 Hz, 0.7H), 8.11 (d, J = 8 Hz, 0.3H), 7.46-7.34 (m, 3H), 7.25, 6.74 (bs, 0.7H), 3.38-3.30 (m, 2H), 1.56-1.47 (m, 2H), 1.33-1.25 (m, 2H), 0.90-0.82 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 162.12, 159.91, 138.80, 138.58, 133.42, 133.18, 131.77, 131.63, 131.44, 130.27, 130.12, 127.07, 126.96, 46.35, 41.69, 32.37, 30.37, 19.77, 19.44, 13.54, 13.46. HRMS (ESI): calculated for $\text{C}_{11}\text{H}_{16}\text{ClN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 275. 0616; found: 275. 0610.




***N'*-((3-bromophenyl)sulfonyl)-*N*-butylformimidamide (*E*-*syn/anti*=7:3) (5e):** yellow oil, 144.2 mg, 90% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.28(d, J =5.2 Hz, 0.7H), 8.07(d, J =13.2 Hz, 0.3H), 7.98-7.94 (m, 1H), 7.78-7.73 (m, 1H), 7.64-7.61 (m, 1H), 7.35-7.30 (m, 1H), 7.25, 7.18 (bs, 0.3H), 6.69 (bs, 0.7H), 3.38-3.30 (m, 2H), 1.78, 1.55-1.48 (m, 2H), 1.34-1.27 (m, 2H), 0.92-0.84 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.65, 158.25, 143.99, 143.62, 135.20, 134.96, 130.49, 130.35, 129.34, 129.32, 124.96, 124.91, 122.79, 122.62, 46.38, 41.71, 32.32, 30.40, 19.83, 19.49, 13.57, 13.48. HRMS (ESI): calculated for $\text{C}_{11}\text{H}_{16}\text{BrN}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 319.0110; found: 319.0102.



***N*-butyl-*N'*-(naphthalen-2-ylsulfonyl)formimidamide (E-*syn/anti*=7:3) (5f):** white solid, 114.1 mg, 79% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.41(s, 1H), 8.40 (s, 0.7H), 8.17 (bs, 0.3H), 7.90-7.77 (m, 4H), 7.61-7.51(m, 2H), 7.35 (bs, 0.3H), 7.25, 6.80 (bs, 0.7H), 3.36-3.28 (m, 2H), 1.54-1.46 (m, 2H), 1.28-1.23 (m, 2H), 0.87-0.78 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.53, 158.26, 139.09, 138.69, 134.58, 134.49, 132.14, 129.25, 129.15, 129.03, 129.00, 128.54, 128.34, 127.85, 127.80, 127.41, 127.38, 127.24, 127.22, 127.04, 126.98, 122.30, 122.11, 46.31, 41.63, 32.38, 30.39, 19.83, 19.48, 13.54, 13.46. HRMS (ESI): calculated for $\text{C}_{15}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 291.1162; found: 291.1171.




***N*-butyl-*N'*-(pyridin-3-ylsulfonyl)formimidamide (E-*syn/anti*=8:2) (5g):** yellow oil, 90.0 mg, 75% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 9.03 (s, 1H), 8.71 (d, $J=4$ Hz, 1H), 8.30 (d, $J=5.2$ Hz, 0.8H), 8.16-8.10 (m, 1.2H), 7.42-7.39 (m, 1H), 7.28 (bs, 0.2H), 6.85 (bs, 0.8H), 3.39-3.32 (m, 2H), 1.58-1.48 (m, 2H), 1.35-1.27 (m, 2H), 0.92-0.84 (m, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.68, 158.12, 152.52, 152.33, 147.36, 138.82, 138.56, 134.30, 134.20, 123.59, 123.51, 46.34, 41.77, 32.34, 30.40, 19.82, 19.48, 13.53, 13.46. HRMS (ESI): calculated for $\text{C}_{10}\text{H}_{16}\text{N}_3\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 242.0958; found: 242.0972.




***N*-methyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=8:2) (5i):** yellow oil, 54.5 mg, 55% yield. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.28 (d, $J=5.2$ Hz, 0.8H), 8.07 (d, $J=13.6$ Hz, 0.2H), 7.85-7.80 (m, 2H), 7.52-7.42 (m, 3H), 7.10 (bs, 0.2H), 6.84 (bs, 0.8H), 3.04 (d, $J=4.8$ Hz, 0.4H), 2.91 (d, $J=4.8$ Hz, 2.6H). ^{13}C NMR (100 MHz, CDCl_3)


δ 161.44, 158.72, 141.97, 141.69, 132.25, 132.06, 128.93, 128.81, 126.36, 126.30, 28.45. HRMS (ESI): calculated for $C_8H_{11}N_2O_2S$ $[M+H]^+$: 199.0536; found: 199.0533.



***N'*-(phenylsulfonyl)-*N*-propylformimidamide (E-*syn/anti*=7:3) (5j)**: yellow oil, 78.6 mg, 70% yield. 1H -NMR (400 MHz, $CDCl_3$) δ 8.30 (d, J = 5.2 Hz, 0.7H), 8.09 (d, J =14 Hz, 0.3H), 7.83-7.79 (m, 2H), 7.53-7.41 (m, 3H), 7.30 (bs, 0.3H), 6.81 (bs, 0.7H), 3.32-3.22 (m, 2H), 1.60-1.49 (m, 2H), 0.91-0.84 (m, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.59, 158.18, 142.16, 141.79, 132.19, 131.93, 128.91, 128.75, 126.28, 126.27, 48.15, 43.51, 23.68, 21.70, 11.18, 10.80. HRMS (ESI): calculated for $C_{10}H_{15}N_2O_2S$ $[M+H]^+$: 227.0849; found: 227.0840.



***N*-isobutyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=7:3)(5k)**: yellow oil, 84.1 mg, 70% yield. 1H -NMR (400 MHz, $CDCl_3$) δ 8.38(d, J =4.8 Hz, 0.7H), 8.10 (d, J =12.8Hz, 0.3H), 7.85 (t, J =7.2 Hz, 2H), 7.52-7.44 (m, 3H), 7.33 (bs, 0.3H), 6.68 (bs, 0.7H), 3.21 (t, J =6.4 Hz, 1.4H), 3.13 (t, J =6.4 Hz, 0.6H), 1.88-1.80 (m, 1H), 0.93-0.89 (m, 6H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.80, 158.36, 142.23, 141.79, 132.22, 131.91, 128.94, 128.74, 126.38, 53.95, 49.11, 29.27, 27.72, 19.96, 19.52. HRMS (ESI): calculated for $C_{11}H_{17}N_2O_2S$ $[M+H]^+$: 241.1005; found: 241.1009.



***N*-cyclohexyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=7:3)(5l)**: yellow oil, 110.5 mg, 83% yield. 1H -NMR (400 MHz, $CDCl_3$) δ 8.29 (d, J =4.4 Hz, 0.7H), 8.20(d, J =13.2 Hz, 0.3H), 7.87-7.86 (m, 2H), 7.54-7.45 (m, 3H), 7.19 (bs, 0.3H), 6.42 (bs, 0.7H), 3.86 (bs, 0.7H), 3.31 (bs, 0.3H), 1.91-1.61 (m, 5H), 1.35-1.19 (m, 5H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 158.82, 157.11, 142.37, 141.88, 132.18, 131.85, 128.92,


128.73, 126.40, 55.76, 50.66, 33.74, 32.00, 25.25, 24.77, 24.50, 24.40. HRMS(ESI): calculated for $C_{13}H_{19}N_2O_2S$ $[M+H]^+$: 267.1162; found: 267.1165.



N-octyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=7:3) (5m): yellow oil, 94.6 mg, 64% yield. 1H -NMR (400 MHz, $CDCl_3$) δ 8.29 (d, $J=5.6$ Hz, 0.7H), 8.08(d, $J=13.6$ Hz, 0.3H), 7.89-7.79 (m, 2H), 7.53-7.40 (m, 3H), 7.34 (bs, 0.3H), 6.86 (d, $J=4.8$ Hz, 0.7H), 3.34-3.24 (m, 2H), 1.55-1.45 (m, 2H), 1.22-1.17 (m, 10H), 0.86-0.81 (m, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.54, 158.15, 142.21, 141.83, 132.17, 131.90, 128.90, 128.73, 126.27, 126.24, 46.56, 41.87, 31.69, 31.66, 30.38, 29.05, 28.96, 28.37, 26.65, 26.28, 22.56, 14.03. HRMS(ESI): calculated for $C_{15}H_{25}N_2O_2S$ $[M+H]^+$: 297.1631; found: 297.1634.




N-dodecyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=7:3) (5n): yellow oil, 107.7 mg, 61% yield. 1H -NMR (400 MHz, $CDCl_3$) δ 8.31 (d, $J=5.2$ Hz, 0.7H), 8.09 (d, $J=13.6$ Hz, 0.3H), 7.85-7.81 (m, 2H), 7.51-7.42 (m, 3H), 7.13 (bs, 0.3H), 6.51 (bs, 0.7H), 3.36-3.26 (m, 2H), 1.53-1.47 (m, 2H), 1.28-1.19 (m, 18H), 0.88-0.84 (m, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 160.35, 157.98, 142.17, 141.78, 132.66, 132.17, 131.89, 129.08, 128.88, 128.71, 126.37, 126.34, 46.55, 41.91, 31.89, 31.88, 30.42, 29.58, 29.51, 29.48, 29.42, 29.40, 29.31, 29.11, 29.02, 28.46, 26.67, 26.30, 22.65, 14.09. HRMS (ESI): calculated for $C_{19}H_{33}N_2O_2S$ $[M+H]^+$: 353.2257; found: 353.2250.




N-benzyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=8:2) (5o): white solid, 76.4 mg, 53% yield. 1H -NMR (400 MHz, $CDCl_3$) δ 8.35 (d, $J=5.2$ Hz, 0.8H),


8.23(d, $J=12.8$ Hz, 0.2H), 7.82-7.75 (m, 2H), 7.50 (t, $J=7.6$ Hz, 1H), 7.42 (t, $J=8$ Hz, 2H), 7.34-7.20 (m, 5H), 6.56 (bs, 0.8H), 4.51 (d, $J=5.6$ Hz, 1.6H), 4.46 (d, $J=6.4$ Hz, 0.4H), ^{13}C NMR (100 MHz, CDCl_3) δ 160.64, 157.68, 141.88, 141.48, 135.83, 135.70, 132.23, 132.02, 129.09, 128.74, 128.43, 128.08, 127.37, 126.41, 77.33, 77.22, 77.01, 76.70, 50.00, 45.86. HRMS (ESI): calculated for $\text{C}_{14}\text{H}_{15}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 275.0849; found: 275.0845.



***N*-tert-butyl-*N'*-(4-methylphenyl)sulfonylformimidamide (*E*-*syn/anti*=3:7) (5p)**: white solid, 82.4 mg, 65% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.36 (d, $J=5.6$ Hz, 0.3H), 8.23 (d, $J=14$ Hz, 0.7H), 7.70 (d, $J=8.4$ Hz, 2H), 7.24-7.19 (m, 2H), 6.95 (d, $J=12.8$ Hz, 0.7H), 6.56 (d, $J=5.6$ Hz, 0.3H), 3.37 (s, 3H), 1.76, 1.36 (s, 2.7H), 1.31 (s, 6.3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.46, 157.37, 142.63, 142.13, 139.80, 139.16, 129.41, 129.20, 126.36, 126.12, 53.52, 53.23, 30.02, 28.14, 21.44, 21.42. HRMS (ESI): calculated for $\text{C}_{12}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 255.1162; found: 255.1156.




***N*-tert-butyl-*N'*-(phenylsulfonyl)formimidamide (*E*-*syn/anti*=3:7) (5q)**: white solid, 82.6 mg, 69% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.36(d, $J=6\text{Hz}$, 0.3H), 8.25(d, $J=14\text{Hz}$, 0.7H), 7.83(d, $J=7.2\text{Hz}$, 2H), 7.52-7.40(m, 3H), 7.25, 6.89(bs, 0.7H), 6.48(bs, 0.3H), 1.71, 1.37(s, 2.7H), 1.33(s, 6.3H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.59, 157.49, 142.58, 141.97, 132.03, 131.67, 128.83, 128.63, 126.35, 126.09, 77.35, 77.23, 77.03, 76.71, 53.64, 53.32, 30.06, 30.03, 28.16. HRMS (ESI): calculated for $\text{C}_{11}\text{H}_{17}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 241.1005; found: 241.1002.




***N*-tert-butyl-*N'*-((4-nitrophenyl)sulfonyl)formimidamide (E-*syn/anti*=3:7)**


(**5r**): white solid, 116.2 mg, 82% yield, $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 8.30-8.26 (m, 2.3H), 8.23 (s, 0.7H), 8.04-8.01 (m, 2H), 6.80 (d, $J=13.6$ Hz, 0.7H), 6.40 (bs, 0.3H), 1.68, 1.39 (s, 2.7H), 1.37 (s, 6.3H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.76, 157.69, 149.65, 149.54, 148.17, 147.67, 127.75, 127.51, 124.10, 124.03, 54.17, 53.77, 30.07, 28.15. HRMS(ESI): calculated for $\text{C}_{10}\text{H}_{16}\text{N}_3\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 286.0856; found: 286.0852.



***N*-phenyl-*N'*-(phenylsulfonyl)formimidamide (E-*syn/anti*=1:1)(**5t**)**: white solid, 55.9 mg, 43% yield. $^1\text{H-NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 11.32 (bs, 0.5H), 11.09 (bs, 0.5H), 8.78 (s, 0.5H), 8.30 (s, 0.5H), 7.91-7.86 (m, 2H), 7.69-7.57 (m, 4H), 7.41-7.32 (m, 3H), 7.21-7.16 (m, 1H), ^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 157.75, 155.32, 142.39, 142.35, 138.52, 138.01, 132.78, 132.71, 130.07, 129.67, 129.55, 129.51, 126.77, 126.63, 125.73, 125.52, 121.25, 118.48. HRMS (ESI): calculated for $\text{C}_{13}\text{H}_{13}\text{N}_2\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 261.0692; found: 261.0691.




4-ethoxycarbonyl-1H-1,2,3-triazole¹: white solid, 49.5 mg, 70%. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 14.49 (s, 1H), 8.35 (s, 1H), 4.44-4.40 (m, 2H), 1.35 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 161.14, 139.08, 131.40, 61.70, 14.14.




***N*-butyl-4-methylbenzenesulfonamide²**: white solid. $^1\text{H-NMR}$ (400 MHz, CDCl_3) δ 7.75 (d, $J=8$ Hz, 2H), 7.29 (d, $J=8$ Hz, 2H), 4.66 (bs, 1H), 2.91 (t, $J=7.2$ Hz,


2H), 2.41 (s, 1H), 1.45-1.39 (m, 2H), 1.32-1.23 (m, 2H), 0.83 (t, $J=7.2$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 143.27, 136.96, 129.64, 127.07, 42.88, 31.52, 21.48, 19.66, 13.49.




***N,N*-diethyl-*N'*-tosylformimidamide (7a)**³: white solid, 231.5 mg, 91% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.13 (s, 1H), 7.76 (d, $J=8$ Hz, 2H), 7.26-7.23 (m, 2H), 3.49-3.43 (m, 2H), 3.39-3.34 (m, 2H), 2.39 (s, 3H), 1.24 (t, $J=7.2$ Hz, 3H), 1.13 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.16, 142.36, 139.91, 129.37, 126.47, 47.15, 41.02, 29.80, 21.57, 14.62, 12.20




***N'*-((2-chlorophenyl)sulfonyl)-*N,N*-diethylformimidamide (7b)**³: white solid, 230.8 mg, 84% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.27 (s, 1H), 8.20 (d, $J=7.6$ Hz, 1H), 7.42-7.34 (m, 3H), 3.49-3.44 (m, 2H), 3.43-3.38 (m, 2H), 1.27 (t, $J=7.2$ Hz, 3H), 1.13 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 160.03, 139.14, 132.99, 131.60, 131.35, 130.35, 126.95, 47.20, 41.17, 14.58, 12.00.




***N'*-((3-bromophenyl)sulfonyl)-*N,N*-diethylformimidamide (7c)**⁴: white solid, 257.6 mg, 81% yield. ^1H -NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.19 (s, 1H), 7.81-7.80 (m, 1H), 7.49-7.48 (m, 1H), 7.09-7.07 (m, 1H), 3.50-3.44 (m, 2H), 3.39-3.34 (m, 2H), 1.13 (t, $J=7.2$ Hz, 3H), 1.05 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, $\text{DMSO}-d_6$) δ 160.50, 139.91, 134.05, 131.99, 130.97, 129.89, 128.02, 46.90, 41.00, 14.85, 12.23.




***N,N*-diethyl-*N'*-((4-nitrophenyl)sulfonyl)formimidamide (7d)**⁵: white solid, 251.2 mg, 88% yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.32-8.29 (m, 2H), 8.16 (s, 1H), 8.08-8.05 (m, 2H), 3.52-3.47 (m, 2H), 3.45-3.40 (m, 2H), 1.29 (t, *J*=7.2 Hz, 3H), 1.16 (t, *J*=7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.45, 149.65, 148.51, 127.81, 124.14, 47.55, 41.44, 14.59, 12.21.



***N,N*-diethyl-*N'*-(naphthalen-2-ylsulfonyl)formimidamide (7e)**⁴: white solid, 194.6 mg, 67% yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.44 (s, 1H), 8.19 (s, 1H), 7.93-7.82 (m, 4H), 7.59-7.52 (m, 2H), 3.48-3.43 (m, 2H), 3.39-3.34 (m, 2H), 1.23 (t, *J*=7.2 Hz, 3H), 1.11 (t, *J*=7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.17, 139.49, 134.43, 132.17, 129.15, 128.91, 128.21, 127.78, 127.15, 126.87, 122.47, 47.12, 40.98, 14.45, 12.03.




***N,N*-diethyl-*N'*-(pyridin-3-ylsulfonyl)formimidamide (7f)**⁴: yellow oil, 183.4 mg, 76% yield. ¹H-NMR (400 MHz, CDCl₃) δ 9.05 (d, *J*=2 Hz, 1H), 8.70 (dd, *J*=6.4 Hz, 1.6 Hz, 1H), 8.17-8.15 (m, 2H), 7.40-7.37 (m, 1H), 3.50-3.45 (m, 2H), 3.42-3.36 (m, 2H), 1.26 (t, *J*=7.2 Hz, 3H), 1.14 (t, *J*=7.2 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 158.24, 152.26, 147.46, 139.11, 134.04, 123.35, 47.28, 41.16, 14.41, 12.02.




***N'*-((3,5-dimethylisoxazol-4-yl)sulfonyl)-*N,N*-diethylformimidamide (7g)**⁴: yellow oil, 243.8 mg, 94% yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.08 (s, 1H), 3.48-3.42 (m, 2H), 3.40-3.35 (m, 2H), 2.59 (s, 3H), 2.36 (s, 3H), 1.25 (t, *J*=7.2 Hz,


3H), 1.14 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 170.73, 157.72, 157.61, 118.65, 47.15, 41.06, 14.44, 12.49, 11.93, 10.85.




***N'*-(benzylsulfonyl)-*N,N*-diethylformimidamide (7h)**⁴: white solid, 185.6 mg, 73% yield. ^1H -NMR (400 MHz, CDCl_3) δ 7.41 (s, 1H), 7.33-7.29 (m, 5H), 4.25 (s, 2H), 3.44-3.39 (m, 2H), 3.15-3.09 (m, 2H), 1.14 (t, $J=7.2$ Hz, 3H), 1.03 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 159.42, 130.94, 130.45, 128.35, 128.19, 59.61, 46.74, 40.81, 14.40, 11.96.



***N'*-(butylsulfonyl)-*N,N*-diethylformimidamide (7i)**⁶: white solid, 196.2 mg, 89% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.03 (s, 1H), 3.50-3.45 (m, 2H), 3.39-3.34 (m, 2H), 3.02-2.98 (m, 2H), 1.78-1.71 (m, 2H), 1.46-1.40 (m, 2H), 1.25 (t, $J=7.2$ Hz, 3H), 1.18 (t, $J=7.2$ Hz, 3H), 0.92 (t, $J=7.2$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.28, 53.63, 46.96, 40.83, 25.67, 21.56, 14.49, 13.60, 11.95.




***N,N*-dimethyl-*N'*-tosylformimidamide (7j)**⁶: white solid, 226.4 mg, 85% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.14 (s, 1H), 7.78 (d, $J=8$ Hz, 2H), 7.27-7.25 (m, 2H), 3.12 (s, 3H), 3.02 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ 158.20, 141.59, 138.71, 128.45, 125.68, 40.58, 34.66, 20.64.




4-methyl-*N*-(pyrrolidin-1-ylmethylene)benzenesulfonamide (7k)⁷: white solid, 191.8 mg, 76% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.29 (s, 1H), 7.76 (d, $J=8$ Hz, 2H), 7.23 (d, $J=8$ Hz, 2H), 3.56 (t, $J=6.4$ Hz, 2H), 3.44 (t, $J=6.4$ Hz, 2H), 2.37 (s, 3H),


1.94-1.91 (m, 4H). ^{13}C NMR (100 MHz, CDCl_3) δ 155.79, 142.33, 139.66, 129.26, 126.50, 49.93, 46.41, 24.99, 24.32, 21.44.




N-(piperidin-1-ylmethylene)benzenesulfonamide (7l)⁶: white solid, 209.4 mg, 83% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.13 (s, 1H), 7.90-7.88 (m, 2H), 7.51-7.44 (m, 3H), 3.61 (t, $J=5.6$ Hz, 2H), 3.42 (t, $J=5.6$ Hz, 2H), 1.71-1.59 (m, 6H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.49, 142.71, 131.87, 128.81, 126.58, 52.08, 44.85, 26.58, 25.00, 24.11.




4-(tert-butyl)-N-(piperidin-1-ylmethylene)benzenesulfonamide (7m)⁸: white solid, 265 mg, 86% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.13 (s, 1H), 7.80 (d, $J=8.4$ Hz, 2H), 7.46 (d, $J=8.4$ Hz, 2H), 3.60 (t, $J=5.6$ Hz, 2H), 3.40 (t, $J=5.6$ Hz, 2H), 1.70-1.62 (m, 4H), 1.60-1.56 (m, 2H), 1.32 (s, 9H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.42, 155.41, 139.71, 126.35, 125.76, 51.99, 51.99, 44.75, 35.11, 31.24, 29.79, 26.52, 24.96, 24.07.



4-nitro-N-(piperidin-1-ylmethylene)benzenesulfonamide (7n)⁹: white solid, 252.8 mg, 85% yield. ^1H -NMR (400 MHz, CDCl_3) δ 8.32-8.29 (m, 2H), 8.14 (s, 1H), 8.08-8.05 (m, 2H), 3.63 (t, $J=6.4$ Hz, 2H), 3.48-3.45 (m, 2H), 1.72-1.70 (m, 4H), 1.65-1.60 (m, 2H). ^{13}C NMR (100 MHz, CDCl_3) δ 157.56, 149.69, 148.46, 127.91, 124.16, 52.40, 45.14, 26.59, 25.03, 24.00.



4-methyl-N-(morpholinomethylene)benzenesulfonamide (7o)⁶: white solid, 158.4 mg, 59% yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.17 (s, 1H), 7.75 (d, *J*=8.4Hz, 2H), 7.26-7.24 (m, 2H), 3.73 (t, *J*=4.8 Hz, 2H), 3.66 (s, 4H), 3.47 (t, *J*=4.8 Hz, 2H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 157.56, 142.67, 139.13, 129.36, 126.55, 66.78, 65.90, 50.27, 44.17, 21.47.



N-methyl-N-(p-tolyl)-N'-tosylformimidamide(7p): white solid, 202.6 mg, 67% yield. ¹H-NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 7.83 (d, *J*=8.4 Hz), 7.30-7.27 (m, 2H), 7.22 (d, *J*=8 Hz, 2H), 7.08 (d, *J*=8.4 Hz, 2H), 3.42(s, 3H), 2.40 (d, *J*=18.4 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 158.55, 142.98, 141.07, 139.33, 137.64, 130.58, 129.62, 126.96, 122.30, 36.40, 21.72, 21.10. HRMS (ESI): calculated for C₁₆H₁₉N₂O₂S [M+H]⁺: 303.1162; found: 303.1159.

6. References:

1. H. Cha, K. Lee, D. Y. Chi, *Tetrahedron*. 2017, **73**, 2878-2885.
2. P. Qu, C. Sun, J. Ma, F. Li, *Adv. Syn. Catal.* 2014, **356**, 447-459.
3. R. Ding, H. Chen, Y.-L. Xu, H.-T. Tang, Y.-Y. Chen, Y.-M. Pan, *Adv. Synth. Catal.* 2019, **361**, 3656-3660.
4. A. Rouzi, R. Hudabaierdi, A. Wusiman, *Tetrahedron*. 2018, **74**, 2475-2481.
5. S. Wang, Z. Wang, X. Zheng, *Chem. Commun.* 2009, **45**, 7372-7374.
6. W. Yang, D. Huang, X. Zeng, D. Luo, X. Wang, Y. Hu, *Chem. Commun.* 2018, **54**, 8222-8225.
7. S. Chen, Y. Xu, X. Wan, *Org. Lett.* 2011, **13**, 6152-6155.
8. B. Huang, C. Yang, J. Zhou, W. Xia, *Chem. Commun.* 2020, **56**, 5010-5013.
9. P. Trillo, T. Slagbrand, F. Tinnis, H. Adolfsson, *ChemistryOpen* 2017, **6**, 484-487.

7. Copies of ^1H and ^{13}C NMR Spectra




Figure S4: ^1H NMR of compound 5a




Figure S5: ^{13}C NMR of compound 5a




Figure S6: ¹H NMR of compound 5b




Figure S7: ¹³C NMR of compound 5b




Figure S8: ¹H NMR of compound 5c






Figure S9: ¹³C NMR of compound 5c






Figure S12: ¹H NMR of compound 5e




Figure S13: ¹³C NMR of compound 5e




Figure S14: ^1H NMR of compound 5f




Figure S15: ^{13}C NMR of compound 5f




Figure S16: ¹H NMR of compound 5g




Figure S17: ¹³C NMR of compound 5g




Figure S18: ¹H NMR of compound 5i




Figure S19: ¹³C NMR of compound 5i




Figure S20: ¹H NMR of compound 5j




Figure S21: ¹³C NMR of compound 5j




Figure S22: ^1H NMR of compound 5k




Figure S23: ^{13}C NMR of compound 5k




Figure S24: ^1H NMR of compound 5l




Figure S25: ^{13}C NMR of compound 5l




Figure S26: ¹H NMR of compound 5m




Figure S27: ¹³C NMR of compound 5m




Figure S28: ¹H NMR of compound 5n




Figure S29: ¹³C NMR of compound 5n




Figure S30: ¹H NMR of compound **5o**




Figure S31: ¹³C NMR of compound **5o**




Figure S32: ¹H NMR of compound 5p




Figure S33: ¹³C NMR of compound 5p




Figure S34: ¹H NMR of compound 5q




Figure S35: ¹³C NMR of compound 5q




Figure S36: ¹H NMR of compound 5r




Figure S37: ¹³C NMR of compound 5r




Figure S38: ¹H NMR of compound 5s




Figure S39: ¹³C NMR of compound 5s




Figure S40: ¹H NMR of 4-ethoxycarbonyl-1H-1,2,3-triazole




Figure S41: ¹³C NMR of 4-ethoxycarbonyl-1H-1,2,3-triazole




Figure S42: ¹H NMR of *N*-butyl-4-methylbenzenesulfonamide




Figure S43: ¹³C NMR of *N*-butyl-4-methylbenzenesulfonamide




Figure S44: ¹H NMR of compound 7a




Figure S45: ¹³C NMR of compound 7a




Figure S46: ¹H NMR of compound 7b




Figure S47: ¹³C NMR of compound 7b




Figure S48: ¹H NMR of compound 7c




Figure S49: ¹³C NMR of compound 7c




Figure S50: ¹H NMR of compound 7d




Figure S51: ¹³C NMR of compound 7d




Figure S52: ¹H NMR of compound **7e**




Figure S53: ¹³C NMR of compound **7e**




Figure S54: ¹H NMR of compound 7f




Figure S55: ¹³C NMR of compound 7f




Figure S56: ¹H NMR of compound **7g**




Figure S57: ¹³C NMR of compound **7g**




Figure S58: ¹H NMR of compound 7h




Figure S59: ¹³C NMR of compound 7h




Figure S60: ¹H NMR of compound 7i




Figure S61: ¹³C NMR of compound 7i




Figure S62: ¹H NMR of compound 7j




Figure S63: ¹³C NMR of compound 7j




Figure S64: ¹H NMR of compound 7k




Figure S65: ¹³C NMR of compound 7k




Figure S66: ¹H NMR of compound 7I




Figure S67: ¹³C NMR of compound 7I




Figure S68: ¹H NMR of compound 7m




Figure S69: ¹³C NMR of compound 7m




Figure S70: ¹H NMR of compound 7n




Figure S71: ¹³C NMR of compound 7n




Figure S72: ¹H NMR of compound 7o




Figure S73: ¹³C NMR of compound 7o




Figure S74: ^1H NMR of compound 7p




Figure S75: ^{13}C NMR of compound 7p